Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3454 in advanced solid or hematologic tumors
NCT04481607Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3454 in solid tumor (advanced stage) and hematologic neoplasm, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Maximum tolerated dose. Status: unknown.
02
Drugs
TQB3454
03
Conditions
solid tumor (advanced stage)hematologic neoplasm
Beyond the preview
Go deeper on NCT04481607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481607.